Met Life Investment Management, LLC Revance Therapeutics, Inc. Transaction History

Met Life Investment Management, LLC

  • $17.1 Billion
  • Q3 2024

A detailed history of Met Life Investment Management, LLC transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 56,279 shares of RVNC stock, worth $144,637. This represents 0.0% of its overall portfolio holdings.

Number of Shares
56,279
Previous 55,269 1.83%
Holding current value
$144,637
Previous $142,000 1.41%
% of portfolio
0.0%
Previous 0.0%

Shares

42 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
BUY
$2.57 - $2.57 $2,595 - $2,595
1,010 Added 1.83%
56,279 $144,000
Q2 2024

Aug 13, 2024
BUY
$2.34 - $4.73 $44,099 - $89,141
18,846 Added 51.74%
55,269 $142,000
Q1 2024

May 14, 2024
BUY
$4.65 - $9.31 $169,366 - $339,098
36,423 New
36,423 $179,000
Q3 2023

May 09, 2024
BUY
$11.47 - $25.07 $18,959 - $41,440
1,653 Added 3.91%
43,980 $504,000
Q2 2023

Apr 29, 2024
BUY
$24.7 - $37.61 $1.09 Million - $1.65 Million
43,980 New
43,980 $1.11 Million
Q2 2023

Aug 10, 2023
BUY
$24.7 - $37.61 $40,829 - $62,169
1,653 Added 3.91%
43,980 $1.11 Million
Q1 2023

May 09, 2024
BUY
$18.36 - $35.27 $777,123 - $1.49 Million
42,327 New
42,327 $1.36 Billion
Q4 2022

May 10, 2024
BUY
$18.32 - $30.66 $58,624 - $98,112
3,200 Added 8.18%
42,327 $781,000
Q4 2022

Mar 22, 2023
BUY
$18.32 - $30.66 $58,624 - $98,112
3,200 Added 8.18%
42,327 $781,000
Q4 2022

Feb 15, 2023
BUY
$18.32 - $30.66 $58,624 - $98,112
3,200 Added 8.18%
42,327 $781,000
Q3 2022

Jun 14, 2023
SELL
$14.33 - $28.47 $45,856 - $91,104
-3,200 Reduced 7.56%
39,127 $1.06 Million
Q2 2022

Jun 20, 2023
SELL
$11.52 - $20.4 $36,864 - $65,279
-3,200 Reduced 7.56%
39,127 $540,000
Q1 2022

May 10, 2024
BUY
$12.36 - $20.31 $483,609 - $794,669
39,127 New
39,127 $762,000
Q1 2022

Jun 20, 2023
SELL
$12.36 - $20.31 $39,552 - $64,991
-3,200 Reduced 7.56%
39,127 $762,000
Q1 2022

Mar 22, 2023
BUY
$12.36 - $20.31 $169,257 - $278,125
13,694 Added 53.84%
39,127 $762,000
Q1 2022

May 12, 2022
BUY
$12.36 - $20.31 $169,257 - $278,125
13,694 Added 53.84%
39,127 $763,000
Q4 2021

Jun 21, 2023
SELL
$12.46 - $27.87 $210,499 - $470,835
-16,894 Reduced 39.91%
25,433 $415,000
Q3 2021

Jun 21, 2023
SELL
$25.78 - $33.21 $435,527 - $561,049
-16,894 Reduced 39.91%
25,433 $708,000
Q2 2021

Jun 21, 2023
SELL
$26.8 - $31.84 $452,759 - $537,904
-16,894 Reduced 39.91%
25,433 $753,000
Q1 2021

May 17, 2024
SELL
$24.03 - $29.97 $264,089 - $329,370
-10,990 Reduced 30.17%
25,433 $710,000
Q1 2021

Jun 26, 2023
SELL
$24.03 - $29.97 $405,962 - $506,313
-16,894 Reduced 39.91%
25,433 $711 Million
Q4 2020

Jun 22, 2023
SELL
$23.41 - $28.34 $395,488 - $478,775
-16,894 Reduced 39.91%
25,433 $720,000
Q3 2020

Jun 26, 2023
SELL
$23.23 - $34.3 $392,447 - $579,464
-16,894 Reduced 39.91%
25,433 $639,000
Q2 2020

May 24, 2024
SELL
$12.6 - $26.55 $138,474 - $291,784
-10,990 Reduced 30.17%
25,433 $621 Million
Q2 2020

Jun 26, 2023
SELL
$12.6 - $26.55 $212,864 - $448,535
-16,894 Reduced 39.91%
25,433 $621,000
Q2 2020

Mar 22, 2023
BUY
$12.6 - $26.55 $51,471 - $108,456
4,085 Added 19.14%
25,433 $621,000
Q2 2020

Aug 14, 2020
BUY
$12.6 - $26.55 $51,471 - $108,456
4,085 Added 19.14%
25,433 $621,000
Q1 2020

Jul 12, 2023
SELL
$12.46 - $27.81 $261,398 - $583,425
-20,979 Reduced 49.56%
21,348 $315,000
Q4 2019

Jul 12, 2023
SELL
$11.66 - $20.15 $244,615 - $422,726
-20,979 Reduced 49.56%
21,348 $346,000
Q3 2019

Jul 12, 2023
SELL
$10.22 - $14.5 $214,405 - $304,195
-20,979 Reduced 49.56%
21,348 $277,000
Q3 2019

Mar 22, 2023
BUY
$10.22 - $14.5 $59,439 - $84,332
5,816 Added 37.45%
21,348 $277,000
Q3 2019

Nov 14, 2019
BUY
$10.22 - $14.5 $59,439 - $84,332
5,816 Added 37.45%
21,348 $278,000
Q2 2019

Jul 12, 2023
SELL
$10.67 - $15.49 $223,845 - $324,964
-20,979 Reduced 49.56%
21,348 $276,000
Q1 2019

Jul 13, 2023
SELL
$15.4 - $20.39 $412,643 - $546,350
-26,795 Reduced 63.3%
15,532 $244,000
Q4 2018

Jul 13, 2023
SELL
$18.06 - $24.96 $483,917 - $668,803
-26,795 Reduced 63.3%
15,532 $312,000
Q4 2018

Mar 22, 2023
SELL
$18.06 - $24.96 $154,720 - $213,832
-8,567 Reduced 35.55%
15,532 $312,000
Q4 2018

Feb 14, 2019
SELL
$18.06 - $24.96 $154,720 - $213,832
-8,567 Reduced 35.55%
15,532 $313,000
Q3 2018

Jul 13, 2023
SELL
$23.55 - $30.1 $631,022 - $806,529
-26,795 Reduced 63.3%
15,532 $385,000
Q3 2018

Mar 22, 2023
SELL
$23.55 - $30.1 $429,269 - $548,662
-18,228 Reduced 43.06%
24,099 $598,000
Q3 2018

Nov 14, 2018
BUY
$23.55 - $30.1 $201,752 - $257,866
8,567 Added 55.16%
24,099 $599,000
Q2 2018

Aug 15, 2018
BUY
$27.45 - $33.35 $125,089 - $151,975
4,557 Added 41.52%
15,532 $426,000
Q4 2017

Feb 15, 2018
BUY
$24.55 - $36.3 $269,436 - $398,392
10,975
10,975 $392,000

Others Institutions Holding RVNC

# of Institutions
234
Shares Held
82.8M
Call Options Held
680K
Put Options Held
896K
View Full List

About Revance Therapeutics, Inc.

RVNC Quotes by TradingView
  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email